Loading…

ANTIBACTERIAL ACTIVITY OF ROXITHROMYCIN: A LABORATORY EVALUATION

Roxithromycin, formerly known as RU 28965 (9-[O[(2-methoxyethoxy)methyl]oxime]-erythromycin), is a novel 14 atom-membered semisynthetic macrolide with an antibacterial spectrum directed towards Gram-positive cocci and bacilli, Gram-negative cocci and some Parvobacteriaceae. The in vitro antibacteria...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antibiotics 1986, Vol.39(5), pp.660-668
Main Authors: CHANTOT, JEAN-FRANÇOIS, BRYSKIER, ANDRÉ, GASC, JEAN-CLAUDE
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c629t-4b64fb096e3edc990f1cb86ffb822bf2c140a694b083db48d94caf9e5ec182353
cites
container_end_page 668
container_issue 5
container_start_page 660
container_title Journal of antibiotics
container_volume 39
creator CHANTOT, JEAN-FRANÇOIS
BRYSKIER, ANDRÉ
GASC, JEAN-CLAUDE
description Roxithromycin, formerly known as RU 28965 (9-[O[(2-methoxyethoxy)methyl]oxime]-erythromycin), is a novel 14 atom-membered semisynthetic macrolide with an antibacterial spectrum directed towards Gram-positive cocci and bacilli, Gram-negative cocci and some Parvobacteriaceae. The in vitro antibacterial activity of roxithromycin was compared with those of erythromycin and spiramycin against 275 clinical isolates by using 2-fold broth macro-dilution tests. The antibacterial spectrum of roxithromycin and erythromycin were qualitatively comparable (including the bacteriostatic type of activity and the profile of resistance), but minimal inhibitory concentrations of erythromycin were generally one half those of roxithromycin, except for Corynebacterium sp. and Bacteroides fragilis against which the new macrolide was more active. On the other hand, roxithromycin exhibited a superior in vivo antibacterial activity in laboratory animals, being up to six times more potent than erythromycin in curing experimentally infected mice. Roxithromycin showed high blood levels and long half-lives of elimination in rodents after oral administration, and its bioavailability amounted to 72% in mice and 85% in rats, compared to less than 10% for erythromycin. Roxithromycin was widely distributed throughout the body with a high degree of penetration into all tissues, particularly in the lungs.
doi_str_mv 10.7164/antibiotics.39.660
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76955481</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76955481</sourcerecordid><originalsourceid>FETCH-LOGICAL-c629t-4b64fb096e3edc990f1cb86ffb822bf2c140a694b083db48d94caf9e5ec182353</originalsourceid><addsrcrecordid>eNpNkF1LwzAUhoMoOj_-gCD0QrzrTJo0TbwyjqnFukKp4q5CkiVa6T5sugv_vRkbw5tzDrzPOe_hBeASwWGGKLlVi77RzbJvjB9iPqQUHoABYgzFiFB-CAYQJihmLIEn4NT7bwhxhjN2DI5DxylKB-BeTOr8QYzqcZWLIgpD_p7X06h8jKryI6-fq_J1Osond5GICvFQVqIuq2k0fhfFm6jzcnIOjpxqvb3Y9TPw9jiuR89xUT7lI1HEhia8j4mmxGnIqcV2ZjiHDhnNqHOaJYl2iUEEKsqJhgzPNGEzToxy3KbWIJbgFJ-Bm-3dVbf8WVvfy3njjW1btbDLtZcZ5WlKGApgsgVNt_S-s06uumauul-JoNzEJv_FJjGXIbawdLW7vtZzO9uv7HIK-vVOV96o1nVqYRq_x9gGg1nAXrbYt-_Vp93rqgtmrf3vjDhlG_d0W8ITe8p8qU7aBf4D38SOWA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76955481</pqid></control><display><type>article</type><title>ANTIBACTERIAL ACTIVITY OF ROXITHROMYCIN: A LABORATORY EVALUATION</title><source>JSTAGE</source><creator>CHANTOT, JEAN-FRANÇOIS ; BRYSKIER, ANDRÉ ; GASC, JEAN-CLAUDE</creator><creatorcontrib>CHANTOT, JEAN-FRANÇOIS ; BRYSKIER, ANDRÉ ; GASC, JEAN-CLAUDE</creatorcontrib><description>Roxithromycin, formerly known as RU 28965 (9-[O[(2-methoxyethoxy)methyl]oxime]-erythromycin), is a novel 14 atom-membered semisynthetic macrolide with an antibacterial spectrum directed towards Gram-positive cocci and bacilli, Gram-negative cocci and some Parvobacteriaceae. The in vitro antibacterial activity of roxithromycin was compared with those of erythromycin and spiramycin against 275 clinical isolates by using 2-fold broth macro-dilution tests. The antibacterial spectrum of roxithromycin and erythromycin were qualitatively comparable (including the bacteriostatic type of activity and the profile of resistance), but minimal inhibitory concentrations of erythromycin were generally one half those of roxithromycin, except for Corynebacterium sp. and Bacteroides fragilis against which the new macrolide was more active. On the other hand, roxithromycin exhibited a superior in vivo antibacterial activity in laboratory animals, being up to six times more potent than erythromycin in curing experimentally infected mice. Roxithromycin showed high blood levels and long half-lives of elimination in rodents after oral administration, and its bioavailability amounted to 72% in mice and 85% in rats, compared to less than 10% for erythromycin. Roxithromycin was widely distributed throughout the body with a high degree of penetration into all tissues, particularly in the lungs.</description><identifier>ISSN: 0021-8820</identifier><identifier>EISSN: 1881-1469</identifier><identifier>DOI: 10.7164/antibiotics.39.660</identifier><identifier>PMID: 3733515</identifier><identifier>CODEN: JANTAJ</identifier><language>eng</language><publisher>Tokyo: JAPAN ANTIBIOTICS RESEARCH ASSOCIATION</publisher><subject>Animals ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Erythromycin - metabolism ; Erythromycin - pharmacology ; Kinetics ; Leucomycins - metabolism ; Leucomycins - pharmacology ; Male ; Medical sciences ; Mice ; Microbial Sensitivity Tests ; Pharmacology. Drug treatments ; Rats ; Tissue Distribution</subject><ispartof>The Journal of Antibiotics, 1986, Vol.39(5), pp.660-668</ispartof><rights>Japan Antibiotics Research Association</rights><rights>1986 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c629t-4b64fb096e3edc990f1cb86ffb822bf2c140a694b083db48d94caf9e5ec182353</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1882,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=8733507$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3733515$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHANTOT, JEAN-FRANÇOIS</creatorcontrib><creatorcontrib>BRYSKIER, ANDRÉ</creatorcontrib><creatorcontrib>GASC, JEAN-CLAUDE</creatorcontrib><title>ANTIBACTERIAL ACTIVITY OF ROXITHROMYCIN: A LABORATORY EVALUATION</title><title>Journal of antibiotics</title><addtitle>J. Antibiot.</addtitle><description>Roxithromycin, formerly known as RU 28965 (9-[O[(2-methoxyethoxy)methyl]oxime]-erythromycin), is a novel 14 atom-membered semisynthetic macrolide with an antibacterial spectrum directed towards Gram-positive cocci and bacilli, Gram-negative cocci and some Parvobacteriaceae. The in vitro antibacterial activity of roxithromycin was compared with those of erythromycin and spiramycin against 275 clinical isolates by using 2-fold broth macro-dilution tests. The antibacterial spectrum of roxithromycin and erythromycin were qualitatively comparable (including the bacteriostatic type of activity and the profile of resistance), but minimal inhibitory concentrations of erythromycin were generally one half those of roxithromycin, except for Corynebacterium sp. and Bacteroides fragilis against which the new macrolide was more active. On the other hand, roxithromycin exhibited a superior in vivo antibacterial activity in laboratory animals, being up to six times more potent than erythromycin in curing experimentally infected mice. Roxithromycin showed high blood levels and long half-lives of elimination in rodents after oral administration, and its bioavailability amounted to 72% in mice and 85% in rats, compared to less than 10% for erythromycin. Roxithromycin was widely distributed throughout the body with a high degree of penetration into all tissues, particularly in the lungs.</description><subject>Animals</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Erythromycin - metabolism</subject><subject>Erythromycin - pharmacology</subject><subject>Kinetics</subject><subject>Leucomycins - metabolism</subject><subject>Leucomycins - pharmacology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Microbial Sensitivity Tests</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><subject>Tissue Distribution</subject><issn>0021-8820</issn><issn>1881-1469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><recordid>eNpNkF1LwzAUhoMoOj_-gCD0QrzrTJo0TbwyjqnFukKp4q5CkiVa6T5sugv_vRkbw5tzDrzPOe_hBeASwWGGKLlVi77RzbJvjB9iPqQUHoABYgzFiFB-CAYQJihmLIEn4NT7bwhxhjN2DI5DxylKB-BeTOr8QYzqcZWLIgpD_p7X06h8jKryI6-fq_J1Osond5GICvFQVqIuq2k0fhfFm6jzcnIOjpxqvb3Y9TPw9jiuR89xUT7lI1HEhia8j4mmxGnIqcV2ZjiHDhnNqHOaJYl2iUEEKsqJhgzPNGEzToxy3KbWIJbgFJ-Bm-3dVbf8WVvfy3njjW1btbDLtZcZ5WlKGApgsgVNt_S-s06uumauul-JoNzEJv_FJjGXIbawdLW7vtZzO9uv7HIK-vVOV96o1nVqYRq_x9gGg1nAXrbYt-_Vp93rqgtmrf3vjDhlG_d0W8ITe8p8qU7aBf4D38SOWA</recordid><startdate>1986</startdate><enddate>1986</enddate><creator>CHANTOT, JEAN-FRANÇOIS</creator><creator>BRYSKIER, ANDRÉ</creator><creator>GASC, JEAN-CLAUDE</creator><general>JAPAN ANTIBIOTICS RESEARCH ASSOCIATION</general><general>Japan Antibiotics Research Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1986</creationdate><title>ANTIBACTERIAL ACTIVITY OF ROXITHROMYCIN: A LABORATORY EVALUATION</title><author>CHANTOT, JEAN-FRANÇOIS ; BRYSKIER, ANDRÉ ; GASC, JEAN-CLAUDE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c629t-4b64fb096e3edc990f1cb86ffb822bf2c140a694b083db48d94caf9e5ec182353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Animals</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Erythromycin - metabolism</topic><topic>Erythromycin - pharmacology</topic><topic>Kinetics</topic><topic>Leucomycins - metabolism</topic><topic>Leucomycins - pharmacology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Microbial Sensitivity Tests</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHANTOT, JEAN-FRANÇOIS</creatorcontrib><creatorcontrib>BRYSKIER, ANDRÉ</creatorcontrib><creatorcontrib>GASC, JEAN-CLAUDE</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antibiotics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHANTOT, JEAN-FRANÇOIS</au><au>BRYSKIER, ANDRÉ</au><au>GASC, JEAN-CLAUDE</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ANTIBACTERIAL ACTIVITY OF ROXITHROMYCIN: A LABORATORY EVALUATION</atitle><jtitle>Journal of antibiotics</jtitle><addtitle>J. Antibiot.</addtitle><date>1986</date><risdate>1986</risdate><volume>39</volume><issue>5</issue><spage>660</spage><epage>668</epage><pages>660-668</pages><issn>0021-8820</issn><eissn>1881-1469</eissn><coden>JANTAJ</coden><abstract>Roxithromycin, formerly known as RU 28965 (9-[O[(2-methoxyethoxy)methyl]oxime]-erythromycin), is a novel 14 atom-membered semisynthetic macrolide with an antibacterial spectrum directed towards Gram-positive cocci and bacilli, Gram-negative cocci and some Parvobacteriaceae. The in vitro antibacterial activity of roxithromycin was compared with those of erythromycin and spiramycin against 275 clinical isolates by using 2-fold broth macro-dilution tests. The antibacterial spectrum of roxithromycin and erythromycin were qualitatively comparable (including the bacteriostatic type of activity and the profile of resistance), but minimal inhibitory concentrations of erythromycin were generally one half those of roxithromycin, except for Corynebacterium sp. and Bacteroides fragilis against which the new macrolide was more active. On the other hand, roxithromycin exhibited a superior in vivo antibacterial activity in laboratory animals, being up to six times more potent than erythromycin in curing experimentally infected mice. Roxithromycin showed high blood levels and long half-lives of elimination in rodents after oral administration, and its bioavailability amounted to 72% in mice and 85% in rats, compared to less than 10% for erythromycin. Roxithromycin was widely distributed throughout the body with a high degree of penetration into all tissues, particularly in the lungs.</abstract><cop>Tokyo</cop><pub>JAPAN ANTIBIOTICS RESEARCH ASSOCIATION</pub><pmid>3733515</pmid><doi>10.7164/antibiotics.39.660</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-8820
ispartof The Journal of Antibiotics, 1986, Vol.39(5), pp.660-668
issn 0021-8820
1881-1469
language eng
recordid cdi_proquest_miscellaneous_76955481
source JSTAGE
subjects Animals
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Erythromycin - metabolism
Erythromycin - pharmacology
Kinetics
Leucomycins - metabolism
Leucomycins - pharmacology
Male
Medical sciences
Mice
Microbial Sensitivity Tests
Pharmacology. Drug treatments
Rats
Tissue Distribution
title ANTIBACTERIAL ACTIVITY OF ROXITHROMYCIN: A LABORATORY EVALUATION
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A31%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ANTIBACTERIAL%20ACTIVITY%20OF%20ROXITHROMYCIN:%20A%20LABORATORY%20EVALUATION&rft.jtitle=Journal%20of%20antibiotics&rft.au=CHANTOT,%20JEAN-FRAN%C3%87OIS&rft.date=1986&rft.volume=39&rft.issue=5&rft.spage=660&rft.epage=668&rft.pages=660-668&rft.issn=0021-8820&rft.eissn=1881-1469&rft.coden=JANTAJ&rft_id=info:doi/10.7164/antibiotics.39.660&rft_dat=%3Cproquest_cross%3E76955481%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c629t-4b64fb096e3edc990f1cb86ffb822bf2c140a694b083db48d94caf9e5ec182353%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=76955481&rft_id=info:pmid/3733515&rfr_iscdi=true